Please login to the form below
Alexion Pharma
This page shows the latest Alexion Pharma news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris
AstraZeneca’s (AZ) rare disease group subsiduary Alexion has reached a settlement agreement with Chugai Pharmaceutical Co (Chugai). ... The agreement resolves all patent disputes between the two companies regarding Ultomiris (ravulizumab) –
Latest news
-
Alexion and NICE agree confidential discount for Ultomiris use on the NHS
stable after receiving Alexion’s older PNH drug Soliris (eculizumab) for six months or more. ... Compared with Alexion’s older drug, Ultomiris is a cost-effective use of NHS resources, concluded NICE.
-
AstraZeneca to acquire Alexion for $39bn
The deal means AZ will immediately gain assets within Alexion’s commercial portfolio, estimated to be worth around $6bn. ... Rare disease is increasingly becoming an area of focus for big pharma, with the Alexion acquisition marking AZ’s first major
-
Alexion eyes Soliris combo with $930m deal to buy Achillion
Additional shares will be tied to various milestones. Alexion has added to its rare blood disorder pipeline with a $930m agreement to buy smaller biotech Achillion Pharma. ... The drug currently accounts for more than 80% of Alexion’s sales, but is
-
Bluebird and Alexion veterans launch cell and gene venture ElevateBio
Massachusetts. The company was unveiled yesterday by its co-founders David Hallal and Vikas Sinha, previously last chief exec and chief financial officer respectively of Alexion, with ex-Bluebird Bio chief ... Hallal and Sinha left Alexion under a cloud
-
CHMP nod for Alexion, GSK drugs, revocation for Lartruvo
The CHMP recommended 13 medicines last Friday, including Ultomiris, Alexion’s follow-up to its rare disease blockbuster Soliris, and GSK’s single pill, two-drug HIV regimen, Dovato. ... Dova Pharma’s Doptelet (avatrombopag) for the treatment of
More from news
Approximately 0 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
Early access for patients with unmet medical needs
He has held previous commercial and operational roles with Alexion Pharma in Europe, Europe Area Markets, Emerging Markets and recently, before moving to GSK was the General Manager for MEA.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Alexion Pharmaceuticals adds to its board
Judith Reinsdorf recently worked at Johnson Controls. Alexion Pharmaceuticals has appointed Judith Reinsdorf to its board of directors following her role as executive vice president and general counsel of Johnson Controls. ... David Brennan, chairman of
-
Alexion appoints new senior VP for EMEAC region
Camilla Harder Hartvig will lead commercial activities from Zurich, Switzerland. Alexion Pharma has appointed Camilla Harder Hartvig as its senior vice president and head of its EMEAC region. ... Alexion’s global business, and look forward to
-
Alexion Pharmaceutiacal names interim CEO and CFO
suited to lead Alexion as we embark on our next exciting phase of growth. ... We are also delighted that Dave Anderson is joining Alexion as our new chief financial officer.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Amgen reports positive results for Otezla in psoriatic arthritis
- Medscape Education is Focusing on Patient Centricity and Education Outcomes at EHA 2023
- Pfizer reports positive results for elranatamab in multiple myeloma
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
- Adaptive innovation
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- Navigating patients step by step on their clinical trial journey
No results were found
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...
Latest intelligence
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
